News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
601,846 Results
Type
Article (21707)
Company Profile (169)
Press Release (579967)
Multimedia
Podcasts (90)
Webinars (14)
Section
Business (203425)
Career Advice (775)
Deals (31526)
Drug Delivery (102)
Drug Development (67889)
Employer Resources (62)
FDA (13056)
Job Trends (11504)
News (297014)
Policy (26966)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (970)
Accelerated approval (46)
ADA (27)
Adcomms (11)
Allergies (157)
Alliances (42870)
ALS (162)
Alzheimer's disease (1320)
Antibody-drug conjugate (ADC) (382)
Approvals (13740)
Artificial intelligence (537)
ASCO (237)
Autoimmune disease (266)
Automation (42)
Bankruptcy (325)
Best Places to Work (8658)
BIO (47)
Biologics (2)
BIOSECURE Act (11)
Biosimilars (210)
BioSpace Insights (82)
Biotechnology (104)
Bladder cancer (168)
Brain cancer (64)
Breast cancer (634)
Cancer (4743)
Cardiovascular disease (378)
Career advice (671)
Career pathing (19)
CAR-T (233)
CDC (11)
Celiac Disease (1)
Cell therapy (642)
Cervical cancer (42)
Clinical research (60774)
Collaboration (1797)
Commercialization (5)
Company closure (2)
Compensation (1504)
Complete response letters (65)
COVID-19 (1481)
CRISPR (87)
C-suite (1114)
Cystic fibrosis (126)
Data (6931)
Decentralized trials (1)
Denatured (23)
Depression (128)
Dermatology (78)
Diabetes (470)
Diagnostics (5014)
Digital health (48)
Diversity (4)
Diversity, equity & inclusion (18)
Drug discovery (288)
Drug pricing (149)
Drug shortages (16)
Duchenne muscular dystrophy (239)
Earnings (83225)
Editorial (32)
Employer branding (10)
Employer resources (58)
Events (101791)
Executive appointments (999)
FDA (16385)
Fibrodysplasia Ossificans Progressiva (11)
Friedreich's ataxia (22)
Frontotemporal dementia (29)
Funding (1322)
Gene editing (172)
Generative AI (39)
Gene therapy (491)
GLP-1 (724)
Government (3247)
Grass and pollen (5)
Guidances (345)
Healthcare (11953)
Hematology (131)
HIV (61)
Huntington's disease (36)
IgA nephropathy (105)
Immunology and inflammation (193)
Immuno-oncology (83)
Indications (204)
Infectious disease (1728)
Inflammatory bowel disease (177)
Inflation Reduction Act (9)
Influenza (100)
Intellectual property (300)
Interviews (107)
IPO (14302)
IRA (40)
Job creations (3235)
Job search strategy (610)
JPM (34)
Kidney cancer (21)
Labor market (47)
Layoffs (298)
Leadership (13)
Legal (6858)
Licensing (10)
Liver cancer (60)
Longevity (24)
Lung cancer (664)
Lymphoma (357)
Machine learning (37)
Management (18)
Manufacturing (975)
Marketing (12)
MASH (165)
Medical affairs (1)
Medical device (9859)
Medtech (10019)
Mergers & acquisitions (18427)
Metabolic disorders (1137)
mRNA (125)
Multiple sclerosis (145)
NASH (15)
Neurodegenerative disease (320)
Neuropsychiatric disorders (75)
Neuroscience (2554)
Neurotech (1)
NextGen: Class of 2026 (4084)
Non-profit (1631)
Now hiring (28)
Obesity (464)
Opinion (188)
Ovarian cancer (193)
Pain (252)
Pancreatic cancer (240)
Parkinson's disease (285)
Partnered (21)
Patents (607)
Patient recruitment (635)
Peanut (50)
People (52046)
Pharmaceutical (45)
Pharmacy benefit managers (23)
Phase 1 (18578)
Phase 2 (26612)
Phase 3 (20098)
Pipeline (9171)
Policy (194)
Postmarket research (2231)
Preclinical (7695)
Press Release (49)
Prostate cancer (253)
Psychedelics (35)
Radiopharmaceuticals (302)
Rare diseases (897)
Real estate (4626)
Recruiting (25)
Regulatory (21367)
Reports (32)
Research institute (1093)
Resumes & cover letters (108)
Rett syndrome (43)
RNA editing (14)
RSV (55)
Schizophrenia (153)
Series A (238)
Series B (170)
Service/supplier (6)
Sickle cell disease (99)
Special edition (14)
Spinal muscular atrophy (146)
Sponsored (21)
Startups (2918)
State (2)
Stomach cancer (10)
Supply chain (102)
Tariffs (79)
The Weekly (65)
Vaccines (624)
Venture capital (76)
Weight loss (253)
Women's health (109)
Worklife (5)
Date
Today (56)
Last 7 days (312)
Last 30 days (2048)
Last 365 days (23894)
2026 (15757)
2025 (24053)
2024 (28143)
2023 (32288)
2022 (42153)
2021 (45540)
2020 (42078)
2019 (31778)
2018 (24239)
2017 (25661)
2016 (24525)
2015 (30334)
2014 (26279)
2013 (22606)
2012 (24557)
2011 (24877)
2010 (24150)
Location
Africa (518)
Alabama (82)
Alaska (3)
Arizona (341)
Arkansas (13)
Asia (31159)
Australia (4410)
California (12813)
Canada (3871)
China (1081)
Colorado (519)
Connecticut (472)
Delaware (279)
Europe (59024)
Florida (1950)
Georgia (416)
Hawaii (3)
Idaho (51)
Illinois (883)
India (105)
Indiana (569)
Iowa (20)
Japan (576)
Kansas (119)
Kentucky (37)
Louisiana (32)
Maine (30)
Maryland (1422)
Massachusetts (8862)
Michigan (326)
Minnesota (617)
Mississippi (5)
Missouri (121)
Montana (28)
Nebraska (16)
Nevada (121)
New Hampshire (73)
New Jersey (3335)
New Mexico (18)
New York (3145)
North Carolina (1559)
North Dakota (4)
Northern California (6440)
Ohio (331)
Oklahoma (17)
Oregon (34)
Pennsylvania (2478)
Puerto Rico (27)
Rhode Island (36)
South America (790)
South Carolina (80)
South Dakota (1)
Southern California (5261)
Tennessee (153)
Texas (2102)
United States (43757)
Utah (390)
Vermont (2)
Virginia (270)
Washington D.C. (52)
Washington State (1000)
West Virginia (2)
Wisconsin (109)
Wyoming (2)
601,846 Results for "novartis pharmaceuticals canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novartis receives Health Canada approval for (Pr)RHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU
July 27, 2026
·
4 min read
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for their recently approved IgAN therapies Fabhalta and Trutakna.
July 20, 2026
·
2 min read
·
Tristan Manalac
Manucturing
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
August 25, 2026
·
4 min read
·
Nick Paul Taylor
Press Releases
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets)
June 4, 2026
·
4 min read
Press Releases
Novartis Canada and SP Quebec Celebrate 16 Years of Partnership Through Annual MS Tri-Challenge Fundraiser
June 24, 2026
·
4 min read
Radiopharmaceuticals
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.
July 22, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Novartis Canada Recognizes Next Generation of Oncology Innovators Through NOYCIA Awards at ASCO
May 26, 2026
·
4 min read
Press Releases
Novartis receives Health Canada approval for VANRAFIA™ (atrasentan tablet) for proteinuria reduction in adults with primary immunoglobulin A nephropathy (IgAN)
July 13, 2026
·
2 min read
Press Releases
Novartis Canada launches third edition of its Health Equity Initiative, prioritizing Women’s Health
May 14, 2026
·
4 min read
Earnings
Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals
Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table.
July 21, 2026
·
2 min read
·
Tristan Manalac
1 of 60,185
Next
